FDA Seeks To Stay Perrigo Suit Over Delayed Rating Update

By Brian Mahoney (April 14, 2014, 5:15 PM EDT) -- The U.S. Food and Drug Administration on Thursday asked a D.C. federal judge to stay a suit from Perrigo Israel Pharmaceuticals Ltd. alleging the agency has failed to update its records to reflect the "therapeutic equivalence" rating of Perrigo's generic testosterone gel product, blasting the company for asserting "speculative harms" in its complaint....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!